{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T22:31:35Z","timestamp":1721601095834},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Research grants from Department of Science and Technology of Sichuan Province","award":["No. 2019JDPT0007."],"award-info":[{"award-number":["No. 2019JDPT0007."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Roxadustat has been shown effective in treating patients with anemia due to chronic kidney disease. However, its long-term effect on clinical outcomes and socioeconomic burden and safety remains unclear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods\/Design<\/jats:title><jats:p>This is a multicenter, prospective, longitudinal observational cohort study assessing if Roxadustat improves prognosis in dialysis patients. Primary outcomes will be major adverse cardiovascular events (MACE), defined as composites of cardiovascular death, myocardial infarction, cerebral infarction, hospitalization because of heart failure; all-cause mortality, and annual economic costs in two years. The data will be collected via Research electronic data capture (REDCap) based database as well as software-based dialysis registry of Sichuan province. The primary outcomes for the ROAD study participants will be compared with those in the dialysis registry cohort. Data at baseline and study follow up will also be compared to assess the association between Roxadustat and long-term clinical outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>The main objective of this study is to the assess long-term association of Roxadustat on MACE, all-cause mortality, socio-economic burden, safety in dialysis patients, which will provide guidance for designing further large randomized controlled trials to investigate this clinic question.<\/jats:p><\/jats:sec><jats:sec><jats:title>Study registration<\/jats:title><jats:p>The study has been registered in Chinese Clinical Trials Registry (ROAD, ROxadustat in treating Anemia in Dialysis patients, registration number ChiCTR1900025765) and provincial observational cohort database (Renal disEAse observational CoHort database, REACH, ChiCTR1900024926), registered 07 September 2019,<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\">http:\/\/www.chictr.org.cn<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12882-021-02229-w","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T09:03:14Z","timestamp":1610528594000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Roxadustat in treating anemia in dialysis patients (ROAD): protocol and rationale of a multicenter prospective observational cohort study"],"prefix":"10.1186","volume":"22","author":[{"given":"Yaling","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hen","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda Y","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanrong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingdong","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoling","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feifei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinxi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongmei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shide","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guisen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daqing","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,13]]},"reference":[{"key":"2229_CR1","unstructured":"Borut C, Gitanjali PSA, Steven P. Z, R. CA. An Exploratory Study of Daprodustat in Erythropoietin-Hyporesponsive Subjects. Kidney International Reports. 2018:S2468024918300408-."},{"issue":"9818","key":"2229_CR2","first-page":"0","volume":"379","author":"L Zhang","year":"2012","unstructured":"Zhang L, Fang W, Li W, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012;379(9818):0\u2013822.","journal-title":"Lancet"},{"key":"2229_CR3","unstructured":"T O, M TA R, M U. Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study. Therapeutic apheresis and dialysis: official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy. 2019."},{"issue":"8","key":"2229_CR4","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3949\/ccjm.83a.15065","volume":"83","author":"G Nakhoul","year":"2016","unstructured":"Nakhoul G, Simon JF. Anemia of chronic kidney disease: Treat it, but not too aggressively. Cleve Clin J Med. 2016;83(8):613\u201324.","journal-title":"Cleve Clin J Med"},{"issue":"3","key":"2229_CR5","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1681\/ASN.V103610","volume":"10","author":"J MA, Ebben","year":"1999","unstructured":"JENNIE Z. MA, Ebben J, XIA H, Collins AJ. Hematocrit Level and Associated Mortality in Hemodialysis Patients. Journal of the American Society of Nephrology 1999;10(3):610\u20139.","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"2229_CR6","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1681\/ASN.2005020183","volume":"17","author":"MA Walker","year":"2006","unstructured":"Walker MA. Anemia as a Predictor of Cardiovascular Events in Patients with Elevated Serum Creatinine. Journal of the American Society of Nephrology. 2006;17(8):2293\u20138.","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"2229_CR7","first-page":"53","volume":"28","author":"RN Foley","year":"1996","unstructured":"Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. 1996;28(1):53\u201361.","journal-title":"The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease."},{"key":"2229_CR8","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","volume":"381","author":"N Chen","year":"2019","unstructured":"Chen N, Hao C, Peng X, Lin H. Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis. The New England Journal of Medicine. 2019;381:1001\u201310.","journal-title":"The New England Journal of Medicine."},{"key":"2229_CR9","first-page":"1","volume":"1","author":"L Francesco","year":"2004","unstructured":"Francesco L, Pisoni RL, Christian C, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrology Dialysis Transplantation. 2004;1:1.","journal-title":"Nephrology Dialysis Transplantation."},{"key":"2229_CR10","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1056\/NEJMoa065485","volume":"355","author":"SINGH A","year":"2006","unstructured":"SINGH A. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085\u201398.","journal-title":"N Engl J Med"},{"key":"2229_CR11","doi-asserted-by":"crossref","unstructured":"Chen N, Hao C, Liu B-C, Lin H, Wang C. X C. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis. The New England Journal of Medicine. 2019;12(381):1011\u201322.","DOI":"10.1056\/NEJMoa1901713"},{"key":"2229_CR12","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1007\/s12325-019-00943-4","volume":"36","author":"T Akizawa","year":"2019","unstructured":"Akizawa T, Iwasaki M, Otsuka T. Roxadustat Treatment of Chronic Kidney DiseaseAssociated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial. Advances in Therapy. 2019;36:1438\u201354.","journal-title":"Advances in Therapy"},{"key":"2229_CR13","first-page":"10","volume":"10","author":"B Anatole","year":"2015","unstructured":"Anatole B, Robert P, Joachim H, et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrology Dialysis Transplantation. 2015;10:10.","journal-title":"Nephrology Dialysis Transplantation."},{"issue":"2","key":"2229_CR14","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"key":"2229_CR15","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95:103208.","journal-title":"J Biomed Inform"},{"issue":"12","key":"2229_CR16","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.2215\/CJN.01380219","volume":"14","author":"F Locatelli","year":"2019","unstructured":"Locatelli F, Hannedouche T, Fishbane S, Morgan Z, Oguey D, White WB. Cardiovascular Safety and All-Cause Mortality of Methoxy Polyethylene Glycol-Epoetin Beta and Other Erythropoiesis-Stimulating Agents in Anemia of CKD: A Randomized Noninferiority Trial. Clinical journal of the American Society of Nephrology: CJASN. 2019;14(12):1701\u201310.","journal-title":"Clinical journal of the American Society of Nephrology: CJASN"},{"issue":"3","key":"2229_CR17","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1053\/j.ajkd.2018.10.006","volume":"73","author":"FR Mc Causland","year":"2019","unstructured":"Mc Causland FR, Claggett B, Burdmann EA, et al. Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American journal of kidney diseases: the official journal of the National Kidney Foundation. 2019;73(3):309\u201315.","journal-title":"American journal of kidney diseases: the official journal of the National Kidney Foundation"},{"issue":"6","key":"2229_CR18","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/13696998.2019.1588738","volume":"22","author":"B Spinowitz","year":"2019","unstructured":"Spinowitz B, Pecoits-Filho R, Winkelmayer WC, et al. Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review. J Med Econ. 2019;22(6):593\u2013604.","journal-title":"J Med Econ"},{"issue":"4","key":"2229_CR19","doi-asserted-by":"publisher","first-page":"726","DOI":"10.2215\/CJN.04950908","volume":"4","author":"RN Foley","year":"2009","unstructured":"Foley RN, Curtis BM, Parfrey PS. Erythropoietin therapy, hemoglobin targets, and quality of life in healthy hemodialysis patients: a randomized trial. Clinical journal of the American Society of Nephrology: CJASN. 2009;4(4):726\u201333.","journal-title":"Clinical journal of the American Society of Nephrology: CJASN"},{"issue":"6","key":"2229_CR20","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.2215\/CJN.02100508","volume":"3","author":"RN Foley","year":"2008","unstructured":"Foley RN, Curtis BM, Parfrey PS. Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy. Clinical journal of the American Society of Nephrology: CJASN. 2008;3(6):1669\u201375.","journal-title":"Clinical journal of the American Society of Nephrology: CJASN"},{"issue":"5","key":"2229_CR21","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/1744-9987.12712","volume":"22","author":"T Akizawa","year":"2018","unstructured":"Akizawa T, Okumura H, Alexandre AF, Fukushima A, Kiyabu G, Dorey J. Burden of Anemia in Chronic Kidney Disease Patients in Japan: A Literature Review. Therapeutic apheresis dialysis: official peer-reviewed journal of the International Society for Apheresis the Japanese Society for Apheresis the Japanese Society for Dialysis Therapy. 2018;22(5):444\u201356.","journal-title":"Therapeutic apheresis dialysis: official peer-reviewed journal of the International Society for Apheresis the Japanese Society for Apheresis the Japanese Society for Dialysis Therapy"},{"issue":"20","key":"2229_CR22","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa062276","volume":"355","author":"TB Drueke","year":"2006","unstructured":"Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. The New England journal of medicine. 2006;355(20):2071\u201384.","journal-title":"The New England journal of medicine"},{"issue":"20","key":"2229_CR23","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1056\/NEJMoa065485","volume":"355","author":"AK Singh","year":"2006","unstructured":"Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. The New England journal of medicine. 2006;355(20):2085\u201398.","journal-title":"The New England journal of medicine"},{"issue":"5","key":"2229_CR24","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1056\/NEJMoa1810742","volume":"380","author":"IC Macdougall","year":"2019","unstructured":"Macdougall IC, White C, Anker SD, et al. Intravenous Iron in Patients Undergoing Maintenance Hemodialysis. The New England journal of medicine. 2019;380(5):447\u201358.","journal-title":"The New England journal of medicine"},{"issue":"9","key":"2229_CR25","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJM199808273390903","volume":"339","author":"A Besarab","year":"1998","unstructured":"Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. The New England journal of medicine. 1998;339(9):584\u201390.","journal-title":"The New England journal of medicine"},{"issue":"12","key":"2229_CR26","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1056\/NEJMoa1005109","volume":"363","author":"SD Solomon","year":"2010","unstructured":"Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. The New England journal of medicine. 2010;363(12):1146\u201355.","journal-title":"The New England journal of medicine"},{"issue":"6","key":"2229_CR27","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/ki.2008.295","volume":"74","author":"LA Szczech","year":"2008","unstructured":"Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney international. 2008;74(6):791\u20138.","journal-title":"Kidney international"},{"issue":"3","key":"2229_CR28","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1111\/j.1523-1755.2004.00480.x","volume":"65","author":"C Canavese","year":"2004","unstructured":"Canavese C, Bergamo D, Ciccone G, et al. Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney international. 2004;65(3):1091\u20138.","journal-title":"Kidney international"},{"issue":"5","key":"2229_CR29","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1053\/j.ajkd.2016.05.031","volume":"68","author":"J Luo","year":"2016","unstructured":"Luo J, Jensen DE, Maroni BJ, Brunelli SM. Spectrum and Burden of Erythropoiesis-Stimulating Agent Hyporesponsiveness Among Contemporary Hemodialysis Patients. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2016;68(5):763\u201371.","journal-title":"American journal of kidney diseases: the official journal of the National Kidney Foundation"},{"issue":"7","key":"2229_CR30","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1080\/08860220903082606","volume":"31","author":"J Malyszko","year":"2009","unstructured":"Malyszko J, Malyszko JS, Mysliwiec M. Hyporesponsiveness to erythropoietin therapy in hemodialyzed patients: potential role of prohepcidin, hepcidin, and inflammation. Renal failure. 2009;31(7):544\u20138.","journal-title":"Renal failure"},{"issue":"1","key":"2229_CR31","doi-asserted-by":"publisher","first-page":"28","DOI":"10.4161\/cc.7.1.5145","volume":"7","author":"C Peyssonnaux","year":"2008","unstructured":"Peyssonnaux C, Nizet V, Johnson RS. Role of the hypoxia inducible factors HIF in iron metabolism. Cell Cycle. 2008;7(1):28\u201332.","journal-title":"Cell Cycle"},{"issue":"12","key":"2229_CR32","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.1073\/pnas.92.12.5510","volume":"92","author":"GL Wang","year":"1995","unstructured":"Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995;92(12):5510\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2229_CR33","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/S0959-437X(98)80016-6","volume":"8","author":"GL Semenza","year":"1998","unstructured":"Semenza GL. Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Curr Opin Genet Dev. 1998;8(5):588\u201394.","journal-title":"Curr Opin Genet Dev"},{"issue":"23","key":"2229_CR34","doi-asserted-by":"publisher","first-page":"720","DOI":"10.21037\/atm.2019.12.18","volume":"7","author":"L Jia","year":"2019","unstructured":"Jia L, Dong X, Yang J, Jia R, Zhang H. Effectiveness of hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat on renal anemia in non-dialysis-dependent chronic kidney disease: a systematic review and meta-analysis. Ann Transl Med. 2019;7(23):720.","journal-title":"Ann Transl Med"},{"key":"2229_CR35","doi-asserted-by":"publisher","first-page":"104747","DOI":"10.1016\/j.phrs.2020.104747","volume":"155","author":"J Liu","year":"2020","unstructured":"Liu J, Zhang A, Hayden JC, et al. Roxadustat (FG-4592) treatment for anemia in dialysis-dependent (DD) and not dialysis-dependent (NDD) chronic kidney disease patients: A systematic review and meta-analysis. Pharmacol Res. 2020;155:104747.","journal-title":"Pharmacol Res"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02229-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-021-02229-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02229-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,11]],"date-time":"2022-12-11T11:27:42Z","timestamp":1670758062000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-021-02229-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,13]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2229"],"URL":"https:\/\/doi.org\/10.1186\/s12882-021-02229-w","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,13]]},"assertion":[{"value":"15 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Institutional Review Board at Sichuan Provincial People\u2019s Hospital (2019\u2009\u2212\u2009196). The informed consent obtained from study participants will be written.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}